The DOI matches its Crossref record; 229 of the 234 references it cites were found in a registry or an index; 29 of the 182 sources its claims cite were checked for support.
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Open accessAbstract
Cancer of the colon and rectum (CRC) has been identified among the three most prevalent types of cancer and cancer-related deaths for both sexes. Even though significant progress in surgical and chemotherapeutic techniques has markedly improved disease-free and overall survival rates in contrast to those three decades ago, recent years have seen a stagnation in these improvements. This underscores the need for new therapies aiming to augment patient outcomes. A number of emerging strategies, such as immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT), have exhibited promising outcomes not only in preclinical but also in clinical settings. Additionally, a thorough appreciation of the underlying biology has expanded the scope of research into potential therapeutic interventions. For instance, the pivotal role of altered telomere length in early CRC carcinogenesis, leading to chromosomal instability and telomere dysfunction, presents a promising avenue for future treatments. Thus, this review explores the advancements in CRC immunotherapy and telomere-targeted therapies, examining potential synergies and how these novel treatment modalities intersect to potentially enhance each other’s efficacy, paving the way for promising future therapeutic advancements.
Overview
CoChat Summary
TL;DR
This narrative review summarizes current and emerging immunotherapy for colorectal cancer (CRC), including immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), vaccines, and telomere/telomerase-targeted strategies. It highlights dMMR/MSI-H as the main immunotherapy-responsive subset and proposes telomere length and telomerase activity as potential prognostic/predictive biomarkers and adjunct targets.
Key findings
- dMMR/MSI-H is identified in roughly 15% of all CRC patients and 5% of metastatic CRC (mCRC) patients; by stage, it accounts for about 15–18% of stage II, ~10% of stage III, and ~5% of stage IV cases. ICIs benefit this subset, but approximately 15–29% develop immune resistance.
- FDA-approved ICIs for CRC include nivolumab (since 1 August 2017 for MSI-H/dMMR mCRC, based on CheckMate 142), pembrolizumab (since 29 June 2020 as first-line for unresectable or metastatic MSI-H/dMMR CRC, based on KEYNOTE-177), and nivolumab plus ipilimumab for previously treated MSI-H/dMMR mCRC. Atezolizumab did not achieve its primary endpoint of improved overall survival in previously treated mCRC.
- As of January 2024, 14 clinical trials were underway assessing TIL cells for CRC; TIL therapy produced objective regression of multiple lung metastatic lesions in mCRC after infusion of HLA-C*08:02-restricted TILs targeting KRAS G12D.
- Telomere/telomerase findings: annual telomere shortening is approximately 20–40 base pairs; telomerase activity is detected in 80–100% of CRC tumor samples versus 9–53% of normal mucosa samples; high TERT and/or telomerase activity is typically associated with poorer prognosis. Longer telomere length was associated with better overall survival regardless of cancer type in one cited study, but had no effect on response to ICI therapy.
Methods
- Design: narrative review of immunotherapy and telomere-targeted therapies in CRC.
- Data: published preclinical and clinical literature, including cited phase II/III trials, meta-analyses, and ClinicalTrials.gov registrations.
- Analysis: qualitative synthesis of immune checkpoint biology, ACT, vaccine platforms, biomarkers, and telomere/telomerase dynamics; no systematic search strategy, meta-analysis, or primary patient data are described.
Limitations
- Stated limitations: Not stated in the paper.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, inclusion criteria, or risk-of-bias assessment, so selection and publication biases cannot be excluded.
- Evident from the text: many cited findings come from heterogeneous settings (preclinical models, phase I/II trials, retrospective studies, and ongoing trials), and proposed synergies between telomere status and ICIs/ACT are largely presented as hypotheses rather than tested in the reviewed clinical trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
23 Valid · 4 Not valid · 117 Not checked · 15 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast to ICIs that greatly exert their action through antagonism of suppressor T-cell receptors, ACT providesits anticarcinogenic effect through isolating the expansion of a great volume of T cells that may overcome certain suppressive immunomodulatory parameters [19].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 1. Introduction
What the sources say
- Supportedcites [19] Yi, 2022, Advances in adoptive cellular therapy for colorectal cancer: A narrative review, Ann. Transl. Med. source
The Introduction (p.1) of Yi & Hu 2022 states verbatim in substance: 'Unlike ICIs that block T-cell suppressor receptors, ACT exhibits antitumor activity by isolated expansion of large numbers of T cells, which may allow bypassing certain suppressive immunomodulatory factors.' The citing sentence reproduces this contrast (ICI = antagonist of suppressor T-cell receptors; ACT = isolated expansion of a large T-cell volume overcoming suppressive immunomodulatory parameters) with the same hedged modality ('may'). No additional reading was needed. (LLM, conf=0.95)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, despite the high rate of durable responses, a fraction of them will develop immune resistance that can outweigh prolonged survival outcomes (approximately 15–29%) [12,15,16].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 1. Introduction
What the sources say
- Supportedcites [12] Borelli, B., Antoniotti, C., Carullo, M., Germani, M.M., Conca, V., and Masi, G. (2022). Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability. Cancers, 14. source
The Introduction states that, despite durable responses and prolonged survival with ICIs in dMMR/MSI-H metastatic colorectal cancer, 15–29% of patients experience primary refractoriness or only short-term clinical benefit. Section 4 also describes primary and acquired resistance, supporting the citing sentence’s broader reference to immune resistance. (LLM, conf=0.92)
- Partly supportedcites [15] Shiu, 2020, Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Radiographic Response section reports progressive disease as the best response in 29.4% of pembrolizumab-treated patients, and the Discussion calls nonresponse in a subgroup “apparent resistance.” The Duration of Response section reports durable responses, but the paper does not establish that 15–29% developed resistance after responding or that resistance outweighed a prolonged-survival benefit. (LLM, conf=0.86)
- Partly supportedcites [16] Lenz, 2022, First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study, J. Clin. Oncol. sourceExperimental — accuracy not yet measured
The Efficacy section reports durable responses and a 13–16% progressive-disease rate with first-line nivolumab plus ipilimumab. The Discussion reports a 29% progressive-disease rate with pembrolizumab and suggests possible intrinsic resistance, but it does not establish that 15–29% develop resistance after responding or that resistance outweighs prolonged survival. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, it is also well established that immune responses may be negatively affected in cases of telomere attrition [27,28].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 1. Introduction
What the sources say
- Could not verifycites [27] Nikolouzakis, 2021, Novel Prognostic Biomarkers in Metastatic and Locally Advanced Colorectal Cancer: Micronuclei Frequency and Telomerase Activity in Peripheral Blood Lymphocytes, Front. Oncol. sourceExperimental — accuracy not yet measured
Our copy of Nikolouzakis et al. (2021) covers telomerase activity (TA) and telomere length in peripheral blood lymphocytes as prognostic biomarkers in metastatic/locally advanced CRC; the Introduction (telomerase/telomere paragraph) links shorter telomeres per cell cycle to 'cellular senescence' as a barrier against cancer, but no passage ties telomere attrition to impaired immune responses. Searches for 'immune response / immunity', 'lymphocyte senescence', and 'telomere attrition' returned only TA results, hTERT signalling pathways (Discussion), the control-group exclusion of autoimmune disease/immune-modifying medication, and reference lists — none state the claim. Nothing contrary is said either, so the point is simply not addressed by this source. (LLM, conf=0.70)
- Supportedcites [28] Weng, 2012, Telomeres and immune competency, Curr. Opin. Immunol. source
The Concluding remarks section states that shortened telomeres in lymphocytes are conceived to have a detrimental impact on their ability to combat pathogens and that 'lymphocytes with short telomeres will have reduced ability to mount a strong and sustained immune response.' The section 'Short telomeres of leukocytes associated with aging and immune dysfunctions' likewise links telomere attrition to replicative impairment/exhaustion of viral-reactive T cells, and 'Potential applications of telomere length measurement in leukocytes' extends this to poor vaccine responses in the elderly. The hedged phrasing of the claim ('may be negatively affected') is matched or exceeded by our copy. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, MSI-H results in the upregulation of immune checkpoint proteins (like PD-1 and PD-L1), facilitating immune evasion via tumor-infiltrating lymphocytes, rather than tumor cells [71].”
- Also stated in: § 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1) · hedged
“Interestingly, current data suggest that cancers with MSI-H exhibit upregulation of immune checkpoint proteins like PD-1 and PD-L1, facilitating immune evasion through tumor-infiltrating lymphocytes rather than tumor cells themselves [71].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 3. Immune Response in CRC
What the sources say
- Partly supportedcites [71] Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov. sourceExperimental — accuracy not yet measured
The Results report higher PD-1 expression on lymphocytes and higher PD-L1 expression in MSI than MSS tumors; the Discussion links these checkpoints to adaptive resistance. However, the Results identify infiltrating myeloid cells—not lymphocytes—as the predominant source of PD-L1. The Discussion also allows that tumor cells may express PD-L1 below the detection limit of the assay. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1) · hedged
Every source the paper cites for this claim was checked and supports it.
In the paper
“For gastrointestinal tumors, such as CRC, the primary hurdle in developing TIL therapy may not lie in the in vitro expansion of bulk TILs but rather in the ability to select and enrich tumor-reactive T cells [142].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 7. Adoptive Cell Therapy (ACT) > 7.2. Tumor-Infiltrating Lymphocyte (TIL) Therapy
What the sources say
- Supportedcites [142] Turcotte, 2013, Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy, J. Immunol. source
The Discussion directly states that the main challenge for TIL therapy in metastatic gastrointestinal cancers may be selecting and enriching tumor-reactive T cells, rather than expanding bulk TILs in vitro. The Clinical-scale TIL expansion section also reports successful expansion of GI cancer-derived TILs. (LLM, conf=0.95)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
78 more claims · 12 with their cited sources checked
Create a free account to see all 159 claims and to verify the 153 references still open.
- It may state two separate claims as one. 50
- Probably not a substantial claim. 37
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Immune checkpoint inhibitors (ICIs) are a class of immunotherapy that is often used to treat MSI High (MSI-H) or dMMR tumors [37].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“This subset of CRC exhibits high immunogenicity due to increased mutational burden, inducing high immune cell infiltration, particularly from tumor-infiltrating lymphocytes [37,38].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 5. Immune Checkpoints > 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1)
“It has been shown that PD-L1 or PD-L2, acting through their ligation to PD-1, may induce anti-cancer immune responses.”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 4. Immune Evasion of CRC
“Additionally, cancer cells can increase immune checkpoint molecules such as PD-L1, resulting in peripheral T cell exhaustion and the inhibition of malignant cell apoptosis [85].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 10. Dynamics of Telomere Length
“Shelterin is a complex of proteins comprising six subunits—TRF1, TRF2, TIN2, TPP1, and POT1 [169].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 10. Dynamics of Telomere Length
“TRF1, TRF2, TIN2, TPP1, and POT1”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 5. Immune Checkpoints > 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1)
“PD-1, also known as CD279”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 5. Immune Checkpoints > 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1)
“The PD-1 ligand (PD-L1), also known as CD279 and B7-H1”
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Programmed Death-Ligand 1 (PD-L1) monoclonal antibodies used against Programmed Death 1 (PD-1) or Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) dramatically augmented the therapeutic armamentarium while also providing significant positive re-appreciation of prognosis across several solid tumors [9–11].”
BackgroundPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“In fact, solid tumors such asnon-small cell lung cancer (NSCLC) and melanoma have retrieved significant therapeutic results from immunotherapy [7,8].”
BackgroundOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“In contrast, tumors with a proficient MMR (pMMR) or MSS phenotype exhibit low immunogenicity [44], leading to decreased expression of checkpoint proteins and low or no T-cell tumor infiltration, explaining their intrinsic resistance to ICIs.”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
Background
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Immune checkpoint inhibitors (ICIs) are a class of immunotherapy that is often used to treat MSI High (MSI-H) or dMMR tumors [37].”
Hedayati, N., Safari, M. H., Milasi, Y. E., Kahkesh, S., Farahani, N., Khoshnazar, S. M., Dorostgou, Z., Alaei, E., Alimohammadi, M., Rahimzadeh, P., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02471-w · Cited by 81
“Conventional therapeutic strategies for CRC include chemotherapy, radiotherapy, surgery, and targeted therapy [123, 124].”
Rahimi, A. R., Baghernejadan, Z., Hazrati, A., Malekpour, K., Samimi, L. N., Najafi, A., Falak, R., & Khorramdelazad, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118014 · Cited by 41
Liu, C.-J., Wang, L., & Tsai, F. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030176 · Cited by 38
“These drugs target hormone receptors on the surface or inside tumor cells, thereby blocking hormone binding or inhibiting hormone production to reduce tumor proliferation.”
Duta-Ion, S. G., Juganaru, I. R., Hotinceanu, I. A., Dan, A., Burtavel, L. M., Coman, M. C., Focșa, I. O., Zaruha, A.-G., Codreanu, P. C., Bohîlțea, L. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312507 · Cited by 25
Metadata
- Authors
- Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A.
- Affiliations
- Department of General Surgery, University General Hospital of Heraklion, 71110 Heraklion, Greece
- University Hospital of Heraklion (GR)
- University of Medicine and Pharmacy of Craiova (RO)
- University of Crete (GR)
- Corresponding author
- Docea, Anca Oana
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-05-24
- Volume
- 16
- Issue
- 11
- Pages
- 1995
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11171065
- OpenAlex
- W4398784015
- Semantic Scholar
- c95ad9da0dd0edfa1ade7cb55cb7fd46410f4713
- Cited by
- 37
- References
- 234
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 4
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, immunotherapy, immune checkpoint inhibitors, adoptive immunotherapy, telomere length, telomere dysfunction, chromosomal instability, carcinogenesis, cancer treatment trends
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy. https://app.cochat.ai/papers/10.3390/cancers16111995
- The paper
- Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024). Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy. Cancers. https://doi.org/10.3390/cancers16111995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.